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In the clinical researcher's perfect world every patient entered
into a randomised controlled clinical trial (RCT) would
satisfy all entry criteria, would complete their allocated treat-
ment as described in the protocol, and would contribute data
records which were complete in all respects. In practice it is
doubtful if this ideal is ever achieved, and hence strategies
have been developed for the analysis of RCTs which seek to
protect their inferential basis from consequent biases. Such a
strategy is 'intention to treat' (ITT) which is frequently
advocated as the preferred approach to analysis. This is
particularly so for major trials designed to establish
definitively the efficacy and safety of a new medication or
medical procedure. Indeed ITT has been endorsed in
regulatory guidelines in Europe and the USA (Nordic Coun-
cil on Medicines, 1989; Food & Drug Administration, 1988).
But is ITT always the preferred approach? Can it always be
satisfactorily applied? Is it a well-defined and well understood
concept?
The subject of ITT regularly arouses debate and con-
troversy. In particular the idea that a patient who has been
randomised to treatment A, but actually receives treatment
B, should be assigned to the group who received A for
analysis purposes is totally incomprehensible to some. This
controversy is fuelled by the fact that there are a large
number of clinical trials, particularly in the early phases of
research, for which ITT would indeed be inappropriate. Fur-
ther fuel is added by the different attitudes to ITT in different
research environments - it is a constant concern in the later
phases of drug regulation, for example, whereas research
workers in the Medical Research Council generally show
greater flexibility, probably because they are less concerned
with satisfying conservative regulatory requirements. It has
even been argued that ITT encourages sloppiness -
'Whatever we do, give the treatment or not, it is OK since
the analysis is by ITT!'.
ITT came to prominence in connection with long-term
RCTs with mortality as their major end-point. Peto and
co-workers laid out the general principles for the design and
analysis of such studies in their comprehensive and highly
influential publications in this journal (Peto et al., 1976,
1977). They did not use the term 'intention to treat' but did
advocate that 'even patients who do not get the proper
treatment must not be withdrawn from the analysis'. Their
guidance is detailed: the various ways in which patients may
fail to complete the study as per protocol are all discussed,
together with the possibility that the patients who so fail may
differ in characteristics, or numbers, from treatment arm to
treatment arm. Such differences are the source of the bias
which ITT attempts to avoid - any analysis which omits
patients is open to bias because it no longer compares the
groups as randomised. However, although Peto and co-
workers do recommend that all properly randomised patients
should be included in the analysis regardless of protocol
deviation, they do leave open the possibility for some inap-
propriately randomised patients to be excluded, and thus
stop short of espousing the inclusion of all randomised
patients.
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Within a few years of these publications a major dispute
concerning the analysis of a clinical trial of sulfinpyrazone in
the prevention of cardiac death after myocardial infarction
(The Anturane Reinfarction Trial Research Group, 1980;
Sherry, 1980; Temple & Pledger, 1980) had helped attitudes
to harden. The interpretation of the results of this study
depended critically on the manner of dealing with ran-
domised patients who failed to satisfy all eligibility criteria,
and also with deaths which occurred after treatment with-
drawal. Regulatory considerations were to the fore and hence
the debate was followed keenly by many of those involved in
similar long-term mortality studies. The study is cited as a
key piece of evidence in the book by Friedman et al. (1982),
in their development of the argument that the primary
analysis of an RCT should include all events, in all ran-
domised patients, occurring during the follow-up period
specified in the protocol, a view which was- subsequently
endorsed by Gail (1985) amongst many others. The literature
surrounding the sulfinpyrazone study gives considerable
insight into the issues at stake. Indeed Peace (Fisher et al.,
1990) claims that it is in connection with this study that the
term 'intent-to-treat' was first used, namely by Sherry (1980).
However this attribution appears misguided because the
phrase 'intention to treat' is used by Bradford Hill (1971) in
the ninth edition of his book and appears to have been
present from the sixth edition (1955) onwards.
What is ITT?
So what do clinical research professionals now understand by
an ITT analysis? In 1990 a work group for the Biopharma-
ceutical Section of the American Statistical Association
(ASA) came to the conclusion that it is one which includes all
randomisedpatients in the groups to which they were randomly
assigned, regardless of their compliance with the entry criteria,
regardless of the treatment they actually received, and regard-
less ofsubsequent withdrawalfrom treatment or deviationfrom
the protocol (Fisher et al., 1990). This is probably the most
widely held view. However, some authors have argued for a
more practical definition. Thus Gillings and Koch (1991)
consider that under most circumstances the ITT population
can be defined as all randomised patients who are known to
have received at least one dose of treatment and who provide
follow-up datafor one or more ofthe key efficacy variables: in
general patients should also be allocated to the treatment
actually received when this differsfrom the one to which they
were randomised. Gillings and Koch further suggest that their
definition need only be reconsidered in any trial in which this
population differs from the population of all patients as
randomised by more than 5%. This working definition has
the appeal of being applicable in a routine manner to a large
proportion of trials but should probably be considered more
as a guide to a practical policy than as a valid definition of
ITT. Indeed those following this guide would be well advised
to look out for, and avoid, specific instances where it woldle1
clearly lead to bias, even if this involves only one or two
patients. The ASA work group definition has the great
advantage of simplicity and would probably achieve the
greatest consensus amongst statisticians. However, it gen-
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erally leaves the research worker with a number of practical
problems to solve during its application.
Even though there does appear to be some consensus on
the definition of ITT, the question of the relative weights to
be placed on the ITT analysis and other analyses raises
additional disagreement. This question led the ASA work
group to have three minority reports. One analysis which is
often contrasted with the ITT analysis is the 'per protocol'
analysis. Such an analysis includes only those patients who
satisfy the entry criteria of the trial and who adhere to the
protocol subsequently. (Here again there is ample room for
different interpretations of what constitutes adherence to the
protocol.) The general idea is that the ITT analysis and the
per protocol analysis represent different extremes so that, if
they lead to the same conclusion, then the strength of that
conclusion is considerably increased. It is when they lead to
different conclusions that troubles arise, as illustrated by the
Anturane Reinfarction Trial (Temple & Pledger, 1980)
already discussed.
Studies of events: advantages
A large number of mortality studies and studies of other
medical end-points such as tumour recurrence are similar in
design to the sulfinpyrazone trial referred to earlier: ran-
domised parallel-group trials of an active agent against
placebo or no treatment. For these trials the concept of ITT
is surely much more than a statement about which data and
which patients should be included in the analysis. It defines
the need to collect total mortality (or some non-fatal end-
point) for all randomised patients for the whole intended
follow-up period regardless of eligibility criteria, lack of com-
pliance, withdrawal from treatment or other deviation from
the ideal. Others have argued that the completeness of the
data is not an ITT issue (Fisher et al., 1990), but this seems a
counterproductive distinction. The emphasis on an overall
ITT strategy to avoid bias in studies of mortality and similar
end-points has had other major beneficial effects on their
design and conduct, apart from encouraging complete follow
up. Entry criteria receive more careful consideration to avoid
subsequent difficulties in analysis. Policies for handling a
number of key issues, such as entry criteria violations and
withdrawal from treatment, are regularly covered in pro-
tocols, in terms of their effect on both the conduct of the
study and also the analysis. Countries or centres where com-
plete follow-up of all patients cannot be guaranteed tend to
be avoided in multi-centre trials. Without these steps an ITT
approach to analysis is somewhat hollow. With them, it is
not only possible to carry out an ITT analysis, but it is also
possible to carry out a wide range of alternative analyses and
hence satisfy the most awkward critic by demonstrating the
robustness of conclusions to assumptions about the protocol
violations and deviations.
It is also important to recall that an ITT analysis corres-
ponds more nearly to the examination of the effect of a
change in treatment policy. From this viewpoint many pro-
tocol deviations simply mirror events which would happen in
normal medical practice, so that estimates of treatment
effects based on the ITT approach are closer to the effects
likely to be encountered in subsequent clinical use. Treat-
ments are not usually administered in tight compliance with a
set of inclusion and exclusion criteria; patients do fail to take
their medication as prescribed. The comparison of all
patients who were allocated to treatment A with all patients
allocated to B subsumes these phenomena, and hence
measures more accurately the likely real impact of replacing
B by A in subsequent clinical practice. This 'pragmatic'
philosophy has been fully described by Schwartz et al. (1980).
The emphasis on ITT in studies of events has been closely
connected with the development of overview methodology, or
meta-analysis. This methodology has proved to be of greatest
value for investigating moderate or small effects of treat-
ments on survival and will be discussed in a subsequent
editorial in this series. Such investigations require very large
numbers of patients to distinguish treatment effects from
random variation reliably. A recent overview of the treat-
ment of early breast cancer provides an impressive example
(Early Breast Cancer Trialists' Collaborative Group, 1992).
The fate of every one of the 74,652 women randomised in
133 trials was sought and an ITT aproach to analysis
adopted. Another valuable example is provided by a meta-
analysis of the use of chemotherapy in advanced ovarian
cancer (Advanced Ovarian Cancer Trialists Group, 1991).
Again an ITT approach was adopted and nearly 80% of the
8,139 patients were followed until death. In overviews of this
magnitude it is essential to be cautious, and an ITT approach
is exactly that. The enhanced statistical power of an overview
is intended to increase the chance of detecting moderate
treatment effects, but it simultaneously increases the chance
of detecting similar sized biases arising from different pat-
terns of loss to follow-up in the alternative treatment arms.
When such large numbers of patients and studies are
involved ITT provides the only practicable way forward. Any
attempt to avoid these biases in some other way, for example
by mathematically modelling the effects of such losses, as one
might with a single trial, would require too much detailed
knowledge of each individual trial.
So for studies of medical events, ITT is better regarded as
a complete trial strategy for design, conduct and analysis
rather than as an approach to analysis alone. Its benefits are
then clear: improved study design and conduct; the ability to
answer pragmatic questions; greater potential to explore the
robustness of the conclusions to assumptions about the
inevitable problems which occur during the trial; easier in-
clusion in overviews.
Studies of events: dangers
Critics of ITT in mortality (and other) studies often focus on
peculiar, or even bizarre, failures in their conduct. Anecdotal
reports include: the patient who was randomised to drug A
at a centre where the stocks of A had run out, and so drug B
was given; the patient given his randomised tablet A who
immediately vomited it back completely and was then suc-
cessfully given a tablet of the next treatment in the random
sequence, B. Should such patients really be analysed as
thought they had received A? Does this really mirror normal
medical practice? Letting such questions influence policy or
occupy the mind for very long is pointless. Events of this
type should undoubtedly be carefully recorded and enum-
erated. However, if a trial contains more than a trivial
number of such peculiarities, then it should probably not be
heavily relied upon. And a trivial number of such peculiar-
ities should not influence the conclusions of the trial. The
best reaction to such oddities is to try to reduce their number
to zero in future.
However, there are some real and widely unappreciated
difficulties with ITT, even in the studies of hard events which
led to its evolution. By no means all studies are designed to
compare an active agent with placebo or no treatment.
Many important trials, perhaps especially those of cancer
therapy, are designed to demonstrate that two treatments or
procedures have similar or equal effects on survival. These
are often called equivalence trials. Can a disfiguring oper-
ation be replaced by a less disfiguring one without impairing
survival? Can a treatment with known survival benefits but
particularly undesirable adverse effects be replaced by one
with fewer adverse effects without losing the survival
benefits? Can the number of fractions of palliative radio-
therapy be reduced in patients with inoperable non-small-cell
lung cancer without sacrificing survival or palliation benefits
(Medical Research Council Lung Cancer Working Party,
1992)? In such a trial an ITT analysis- generally increases the
chance of erroneously concluding that no difference exists.
When we are comparing an active agent with placebo this
increased risk is acceptable and is deliberately incurred. In
these trials ITT is conservative; we only declare a new agent
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so, and the inevitable dilution of the treatment effect in an
ITT analysis makes it harder to achieve this goal and affords
extra statistical protection for the cautious. But when we are
seeking equivalence, the bias is in an anti-conservative direc-
tion. At the extreme, for example, if all patients were with-
drawn from both randomised arms and put on the same
standard therapy, an ITT analysis would conclude that no
difference existed between the original treatments regardless
of their true relative efficacy. However, careful consideration
of the alternatives does not lead to totally abandoning the
ITT analysis. Indeed in equivalence trials the overall ITT
strategy ofcollecting all end-points in all randomised patients
is equally valuable, but the role of the ITT analysis itself
differs. Essentially the ITT analysis and one or more
plausible 'per protocol' analyses need to provide the same
conclusion of no difference before a safe overall conclusion
can be drawn.
There is also one especially weak aspect of a rigid ITT
analysis even in placebo controlled studies. This relates to the
exclusion, or not, of patients who fail to satisfy all entry
criteria. Most authors regard the exclusion of such patients
as theoretically allowable provided the criteria in question are
measured and recorded prior to randomisation so that no
question of treatment related bias can arise. (It is also
desirable for the protocol to state the intention to remove
entry criteria violators and to identify the relevant criteria, so
that no accusations of selective analysis can later arise.) Some
argue that this theoretical option should be exercised only
with great caution (Friedman et al., 1982; Gail, 1985). How-
ever there are occasions when the exclusion of entry criteria
violators is important. Suppose that drug X has been shown
to be effective in mild and moderate disease, but there re-
mains a question as to whether it is effective in severe cases,
and so a trial in severe patients is started. Suppose also that
some patients with moderate disease are inadvertently
entered into this trial. Failure to exclude these patients from
the analysis would bias the results in favour of drug X, or at
any rate would lead to the answering of the wrong question.
However it is important to add that the need to exclude more
than a small number ofpatients for this reason would lead to
serious worries about the care with which the trial had been
carried out.
It is also important to consider the 'competing risk' situa-
tion. Cancer patients may die of heart disease, and vice versa.
The use of total mortality as the primary end-point avoids a
number of potentially difficult theoretical issues and is some-
times recommended, but it may also reduce the sensitivity of
a trial below acceptable levels. In a primary prevention trial
in mild hypertension, for example, the cardiovascular mor-
tality may be quite low. Other causes of mortality are also
likely to be recorded notably, cancer, particularly in older
patient populations. Such a trial is near the extreme of the
feasible, and hence the use of cause-specific cardiovascular
mortality as the primary end-point is particularly attractive
to avoid dilution of the anticipated effect. This can never be
truly ITT, because patients who die from other causes are
irretrievably censored. However the statistical assumptions
which have to be made concerning the randomness of the
other deaths are clear, and more complex statistical models
are also available to explore the sensitivity of the conclusions
to these assumptions if necessary. On balance an analysis of
cause-specific mortality, rather than an ITT analysis of total
mortality, is generally to be preferred, and should be pre-
specified in the protocol in line with the hypothesis under
test. Sometimes, however, more diverse and potentially
interacting effects of treatment on different end-points can be
anticipated. An example of this involving non-fatal end-
points is provided by the study of tamoxifen in the primary
prevention of breast cancer. As well as potentially preventing
breast cancer, tamoxifen may have an equally large or larger
beneficial effect on myocardial infarction because of its lipid
lowering effects. It may also reduce events related to
osteoporosis. Mortality from any of these causes will lead to
censoring which cannot be taken to be random, and for
which ITT provides no answers.
Other measurements
It is outside trials of hard end-points that the troubles for
ITT really begin. Take a trial of a new treatment for pain,
for example, comparing a new active agent against placebo.
The deviations from the protocol are likely to be numerous:
patients are likely to default from both treatment arms,
perhaps in unequal numbers, particularly under conditions of
informed consent; doctors are unlikely to retain in the trial
any patient who develops severe pain if other effective agents
are available; patients may suffer events, such as recurrence,
which require withdrawal; patients may die. These problems
may lead in turn to the disruption of the schedule of
measurements of pain: other reasons for missing data, or
disruption of the schedule, will also occur, ranging from
unavailability of the patient on the intended date, to loss of
records. An ITT strategy (to permit a reliable ITT analysis)
would presumably require the collection of pain measure-
ments at all scheduled visits regardless of withdrawal from
the treatment or the study or any other circumstances. In
practice this is impossible, although more could be done in
this direction than is often realised. A measurement lost is a
measurement lost and it cannot be retrospectively estab-
lished, unlike the patient's survival status.
One way to resolve this dilemma, closely related to a
proposal of Gould (1980), is to create a new variable for each
patient in the trial which measures the overall success of
treatment. Thus each patient may be classified as 'improved,
no change, or worse' in terms of pain. Those with complete
pain scores are easy to classify; if multiple measurements of
pain are made, then a suitable algorithm has to be construc-
ted to summarise these in a single classification. Those who
withdraw because of treatment failure can be classified as
'worse'. Those (if any) who withdraw because they no longer
feel the need for treatment can be classified as 'improved'. In
this way, and often with only a few contentious decisions, a
complete set of data can be created which allows a reliable
ITT analysis. However, it must be recognised that this new
variable is measuring something different from the original
pain measurement. An example of this approach can be
found in the report of a recent study of the treatment of
heart failure (Xamoterol in Severe Heart Failure Study
Group, 1990).
A number of other ways of dealing with missing data,
poor compliance and other protocol deviations have been
described. For example, Murray and Findlay (1988) have
described how missing data may be modelled using the idea
of data being 'missing at random', as defined by Rubin
(1976), and unbiased estimates of treatment differences pro-
duced. The perspective afforded by ITT does not appear to
have any special value in clarifying the issues which these or
other procedures are intended to address.
Studies of pain and other measurements are affected
similarly by the issues which affect hard end-ponts described
above. In particular, equivalence studies in which a propor-
tion of the patients withdraw and subsequently receive a
standard active agent must be treated with even greater
caution. Under many clinical circumstances measurements
taken on the standard therapy are more likely to reflect its
immediate effect than the residual effect of the originally
randomised therapy - for mortality and similar end-points
this is less so. Safety data provide another very important
example of this point: a pure ITT approach to the analysis of
safety simply adds to the risk of failing to identify potential
safety problems, and is therefore never advocated.
Other designs
There are some study designs to which the concept of ITT is
particularly difficult to apply. Cross-over trials are the most
obvious case in point (Senn, 1993), although they do not
feature as commonly in cancer research as in some other
areas of medical research. In two-period cross-over trials
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receive their second treatment and hence provide no com-
parative data. An ITT strategy would probably entail trying
to restart such patients on their second treatment so as to
provide some basis for comparison in each patient. One
reported attempt to do this in a study of angina met with
limited success (Blake & Lewis, 1992). Patient 'preferences'
can sometimes be defined in a cross-over trial even when the
paired data are apparently incomplete (France et al., 1991).
Another option is to restrict analysis to the first period only,
but this would be a salvaging operation suggesting that a
cross-over trial was a misguided design in the first place. All
this should not be taken to imply that deviations from the
protocol are less important in cross-over trials. They are
equally important, and the problems of dealing with them are
greater if anything. However it is not clear what contribution
the concept of ITT makes.
Conclusion
For some clinical trials the concept of ITT is clear in purpose
and execution. These are parallel group studies of mortality
and similar hard end-points in which medical or surgical
intervention is compared with no intervention. The conse-
quences of an ITT strategy for the design, conduct and
analysis of such trials is valuable and well understood.
Outside this restricted set of trials the concept has more
limited value. At worst it may mislead unwary investigators
into inappropriate analyses, e.g. in equivalence studies. At
best it duplicates aspects of more general principles which
can be more clearly expressed. Thus, it is important to
account for all randomised patients in the analysis of a
clinical trial and to explore the effect on the conclusions of
any withdrawals from treatment, deviations from the pro-
tocol and missing data. In pursuit of this aim, it is important
to continue to gather data as completely as possible on all
randomised patients in line with their scheduled assessments
regardless of their compliance with the protocol. This allows
alternative analyses to be tried and reported. (Selective repor-
ting of these analyses is another potential source of bias to be
avoided.) Plans to implement these pointsz4ould be covered
in the study protocol.
Anyone who follows these principles intelligently, and with
a view to minimising bias, need not worry further about
'intention to treat'. Further detailed guidance can be found in
a number of text-books, e.g. Pocock (1983); guidance suitable
for clinical trials related to pharmaceutical development can
be found in Lewis (1988).
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